Literature DB >> 30397736

[Results of the LuPSMA trial show high response rates with low toxicity and pain relief].

S Tschirdewahn1, W P Fendler2.   

Abstract

Entities:  

Mesh：

Year:  2018        PMID： 30397736     DOI： 10.1007/s00120-018-0808-y

Source DB:  PubMed          Journal:  Urologe A        ISSN： 0340-2592            Impact factor:   0.639


× No keyword cloud information.
  3 in total

1.  PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617.

Authors:  Clemens Kratochwil; Frederik L Giesel; Melsa Stefanova; Martina Benešová; Marcus Bronzel; Ali Afshar-Oromieh; Walter Mier; Matthias Eder; Klaus Kopka; Uwe Haberkorn
Journal:  J Nucl Med       Date:  2016-03-16       Impact factor: 10.057

2.  Systemic Radioligand Therapy with (177)Lu Labeled Prostate Specific Membrane Antigen Ligand for Imaging and Therapy in Patients with Metastatic Castration Resistant Prostate Cancer.

Authors:  Matthias M Heck; Margitta Retz; Calogero D'Alessandria; Isabel Rauscher; Klemens Scheidhauer; Tobias Maurer; Enno Storz; Friederike Janssen; Margret Schottelius; Hans-Jürgen Wester; Jürgen E Gschwend; Markus Schwaiger; Robert Tauber; Matthias Eiber
Journal:  J Urol       Date:  2016-03-08       Impact factor: 7.450

3.  German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients.

Authors:  Kambiz Rahbar; Hojjat Ahmadzadehfar; Clemens Kratochwil; Uwe Haberkorn; Michael Schäfers; Markus Essler; Richard P Baum; Harshad R Kulkarni; Matthias Schmidt; Alexander Drzezga; Peter Bartenstein; Andreas Pfestroff; Markus Luster; Ulf Lützen; Marlies Marx; Vikas Prasad; Winfried Brenner; Alexander Heinzel; Felix M Mottaghy; Juri Ruf; Philipp Tobias Meyer; Martin Heuschkel; Maria Eveslage; Martin Bögemann; Wolfgang Peter Fendler; Bernd Joachim Krause
Journal:  J Nucl Med       Date:  2016-10-20       Impact factor: 10.057
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.